Skip to main content
Premium Trial:

Request an Annual Quote

LabCorp's Esoterix and DHMRI Collaborate on Assay Development

NEW YORK (GenomeWeb News) – Laboratory Corporation of America division Esoterix Clinical Trial Services today announced a deal with the David H. Murdock Research Institute for assay development.

As part of the deal, assays developed at DHMRI will be transferred to LabCorp Clinical Trials laboratories worldwide to support global clinical studies. The agreement also provides for the downstream commercialization of companion diagnostics and other biomarker assays upon clinical validation, Esoterix said.

The deal provides LabCorp's clinical trials clients "the most complete suite of biomarker development tools in the industry," David Johnston, senior vice president and global head of clinical trials for LabCorp, said in a statement.

Services available to LabCorp's clients through the DHMRI include biomarker discovery and proof-of-concept assay develop for early- and late-stage drug discovery and development.

Financial and other terms of the deal were not disclosed.

The Scan

Boosters Chasing Variants

The New York Times reports that an FDA advisory panel is to weigh updated booster vaccines for COVID-19.

Not Yet

The World Health Organization says monkeypox is not yet a global emergency, the Washington Post reports.

More Proposed for Federal Research

Science reports that US House of Representatives panels are seeking to increase federal research funding.

PLOS Papers on Breast Cancer Metastasis, Left-Sided Cardiac Defects, SARS-CoV-2 Monitoring

In PLOS this week: link between breast cancer metastasis and CLIC4, sequencing analysis of left-sided cardiac defects, and more.